Literature DB >> 28716891

Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Path to a Dengue Vaccine: Learning from Human Natural Dengue Infection Studies and Vaccine Trials.

Aravinda M de Silva1, Eva Harris2.   

Abstract

Dengue virus (DENV) is the most common arthropod-borne viral disease of humans. Although effective vaccines exist against other flaviviral diseases like yellow fever and Japanese encephalitis, dengue vaccine development is complicated by the presence of four virus serotypes and the possibility of partial immunity enhancing dengue disease severity. Several live attenuated dengue vaccines are being tested in human clinical trials. Initial results are mixed, with variable efficacy depending on DENV serotype and previous DENV exposure. Here, we highlight recent discoveries about the human antibody response to DENV and propose guidelines for advancing development of safe and effective dengue vaccines.
Copyright © 2018 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28716891      PMCID: PMC5983190          DOI: 10.1101/cshperspect.a029371

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Biol        ISSN: 1943-0264            Impact factor:   10.005


  48 in total

1.  Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins.

Authors:  Shee-Mei Lok; Victor Kostyuchenko; Grant E Nybakken; Heather A Holdaway; Anthony J Battisti; Soila Sukupolvi-Petty; Dagmar Sedlak; Daved H Fremont; Paul R Chipman; John T Roehrig; Michael S Diamond; Richard J Kuhn; Michael G Rossmann
Journal:  Nat Struct Mol Biol       Date:  2008-02-10       Impact factor: 15.369

2.  A prospective study of dengue infections in Bangkok.

Authors:  D S Burke; A Nisalak; D E Johnson; R M Scott
Journal:  Am J Trop Med Hyg       Date:  1988-01       Impact factor: 2.345

3.  Preexisting neutralizing antibody responses distinguish clinically inapparent and apparent dengue virus infections in a Sri Lankan pediatric cohort.

Authors:  Kizzmekia S Corbett; Leah Katzelnick; Hasitha Tissera; Ananda Amerasinghe; Aruna Dharshan de Silva; Aravinda M de Silva
Journal:  J Infect Dis       Date:  2014-10-21       Impact factor: 5.226

4.  Dengue viruses cluster antigenically but not as discrete serotypes.

Authors:  Leah C Katzelnick; Judith M Fonville; Gregory D Gromowski; Jose Bustos Arriaga; Angela Green; Sarah L James; Louis Lau; Magelda Montoya; Chunling Wang; Laura A VanBlargan; Colin A Russell; Hlaing Myat Thu; Theodore C Pierson; Philippe Buchy; John G Aaskov; Jorge L Muñoz-Jordán; Nikos Vasilakis; Robert V Gibbons; Robert B Tesh; Albert D M E Osterhaus; Ron A M Fouchier; Anna Durbin; Cameron P Simmons; Edward C Holmes; Eva Harris; Stephen S Whitehead; Derek J Smith
Journal:  Science       Date:  2015-09-18       Impact factor: 47.728

5.  Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease.

Authors:  Sri Rezeki Hadinegoro; Jose Luis Arredondo-García; Maria Rosario Capeding; Carmen Deseda; Tawee Chotpitayasunondh; Reynaldo Dietze; H I Hj Muhammad Ismail; Humberto Reynales; Kriengsak Limkittikul; Doris Maribel Rivera-Medina; Huu Ngoc Tran; Alain Bouckenooghe; Danaya Chansinghakul; Margarita Cortés; Karen Fanouillere; Remi Forrat; Carina Frago; Sophia Gailhardou; Nicholas Jackson; Fernando Noriega; Eric Plennevaux; T Anh Wartel; Betzana Zambrano; Melanie Saville
Journal:  N Engl J Med       Date:  2015-07-27       Impact factor: 91.245

6.  Reduced risk of disease during postsecondary dengue virus infections.

Authors:  Sandra Olkowski; Brett M Forshey; Amy C Morrison; Claudio Rocha; Stalin Vilcarromero; Eric S Halsey; Tadeusz J Kochel; Thomas W Scott; Steven T Stoddard
Journal:  J Infect Dis       Date:  2013-06-17       Impact factor: 5.226

7.  Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: How alterations in assay conditions impact performance.

Authors:  Stephen J Thomas; Ananda Nisalak; Kathryn B Anderson; Daniel H Libraty; Siripen Kalayanarooj; David W Vaughn; Robert Putnak; Robert V Gibbons; Richard Jarman; Timothy P Endy
Journal:  Am J Trop Med Hyg       Date:  2009-11       Impact factor: 2.345

8.  Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand.

Authors:  Timothy P Endy; Ananda Nisalak; Supamit Chunsuttitwat; David W Vaughn; Sharone Green; Francis A Ennis; Alan L Rothman; Daniel H Libraty
Journal:  J Infect Dis       Date:  2004-03-01       Impact factor: 5.226

9.  Potential opportunities and perils of imperfect dengue vaccines.

Authors:  Isabel Rodriguez-Barraquer; Luis Mier-y-Teran-Romero; Ira B Schwartz; Donald S Burke; Derek A T Cummings
Journal:  Vaccine       Date:  2013-11-19       Impact factor: 3.641

10.  DENGUE VIRUS. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers.

Authors:  Guntur Fibriansah; Kristie D Ibarra; Thiam-Seng Ng; Scott A Smith; Joanne L Tan; Xin-Ni Lim; Justin S G Ooi; Victor A Kostyuchenko; Jiaqi Wang; Aravinda M de Silva; Eva Harris; James E Crowe; Shee-Mei Lok
Journal:  Science       Date:  2015-07-03       Impact factor: 47.728

View more
  11 in total

1.  A Combination of Two Human Monoclonal Antibodies Prevents Zika Virus Escape Mutations in Non-human Primates.

Authors:  Jennifer R Keeffe; Koen K A Van Rompay; Priscilla C Olsen; Qiao Wang; Anna Gazumyan; Stephanie A Azzopardi; Dennis Schaefer-Babajew; Yu E Lee; Jackson B Stuart; Anil Singapuri; Jennifer Watanabe; Jodie Usachenko; Amir Ardeshir; Mohsan Saeed; Marianna Agudelo; Thomas Eisenreich; Stylianos Bournazos; Thiago Y Oliveira; Charles M Rice; Lark L Coffey; Margaret R MacDonald; Pamela J Bjorkman; Michel C Nussenzweig; Davide F Robbiani
Journal:  Cell Rep       Date:  2018-11-06       Impact factor: 9.423

2.  Dengue Virus Serotype 1 Conformational Dynamics Confers Virus Strain-Dependent Patterns of Neutralization by Polyclonal Sera.

Authors:  Laura A VanBlargan; Pavle S Milutinovic; Leslie Goo; Christina R DeMaso; Anna P Durbin; Stephen S Whitehead; Theodore C Pierson; Kimberly A Dowd
Journal:  J Virol       Date:  2021-09-22       Impact factor: 5.103

3.  Vaccine-induced antibodies to contemporary strains of dengue virus type 4 show a mechanistic correlate of protective immunity.

Authors:  Emily N Gallichotte; Sandra Henein; Usha Nivarthi; Matthew Delacruz; Trevor Scobey; Matthew Bonaparte; Janice Moser; Alina Munteanu; Ralph Baric; Aravinda M de Silva
Journal:  Cell Rep       Date:  2022-06-07       Impact factor: 9.995

4.  Universal Dengue Vaccine Elicits Neutralizing Antibodies against Strains from All Four Dengue Virus Serotypes.

Authors:  Naoko Uno; Ted M Ross
Journal:  J Virol       Date:  2021-01-28       Impact factor: 5.103

5.  Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003).

Authors:  Laura J White; Ellen F Young; Mark J Stoops; Sandra R Henein; Elizabeth C Adams; Ralph S Baric; Aravinda M de Silva
Journal:  PLoS Negl Trop Dis       Date:  2021-03-12

Review 6.  The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design.

Authors:  Félix A Rey; Karin Stiasny; Marie-Christine Vaney; Mariano Dellarole; Franz X Heinz
Journal:  EMBO Rep       Date:  2017-12-27       Impact factor: 8.807

Review 7.  Ocular Manifestations of Emerging Flaviviruses and the Blood-Retinal Barrier.

Authors:  Sneha Singh; Ashok Kumar
Journal:  Viruses       Date:  2018-09-28       Impact factor: 5.048

Review 8.  Does structurally-mature dengue virion matter in vaccine preparation in post-Dengvaxia era?

Authors:  Jedhan Ucat Galula; Gielenny M Salem; Gwong-Jen J Chang; Day-Yu Chao
Journal:  Hum Vaccin Immunother       Date:  2019-08-23       Impact factor: 3.452

Review 9.  Host Factors That Control Mosquito-Borne Viral Infections in Humans and Their Vector.

Authors:  Chasity E Trammell; Alan G Goodman
Journal:  Viruses       Date:  2021-04-24       Impact factor: 5.048

Review 10.  Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine.

Authors:  Rahul Shukla; Viswanathan Ramasamy; Rajgokul K Shanmugam; Richa Ahuja; Navin Khanna
Journal:  Front Cell Infect Microbiol       Date:  2020-10-22       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.